While prior research has reported that obesity attenuates the antihypertensive effects of ARBs and ACE inhibitors [18], our study provides quantitative insights into BMI-related differences in both blood pressure reduction and metabolic outcomes. This evidence concerns the gene ACE and obesity due to melanocortin 4 receptor deficiency.